2015 target of 45 introductions achieved more than one year ahead of schedule
In April 2015, Bangladesh introduced the pneumococcal vaccine alongside inactivated polio vaccine. We are now reaching one of the world’s largest birth cohorts with two life-saving vaccines. Credit: Gavi/2015/GMB Akash.
Roll-out across three continents
More than 50 Gavi-supported countries have introduced pneumococcal vaccines into their routine programmes.
These vaccines, which protect against the main cause of pneumonia, are complex to develop and produce. In the past, they may have taken up to 15 years to reach developing countries. Thanks to the Vaccine Alliance, these countries can now access the newest vaccines at the same time as high-income countries.
Pneumococcal vaccine roll-outs
Gavi aimed to support pneumococcal vaccine introductions in 45 countries by 2015. We reached this target already in November 2014, 13 months ahead of schedule. By the end of 2015, 54 countries had rolled out the vaccine.
One of these was Bangladesh, which introduced both pneumococcal and inactivated polio vaccines in 2015. Another was Nepal, which continued to roll out the vaccine in the aftermath of a devastating earthquake.
More than 70 million children reached
Our support has helped countries immunise over 76 million children against pneumococcal disease. By the end of 2015, only 15 eligible countries had yet to apply for this type of support.
While coverage levels increased to 35% in 2015, they fell 5 percentage points short of our target. This is due to several factors, including supply shortages in the early years of the programme. Also, introductions were delayed in some countries with large populations.
We are working with partners to ensure that supply of the vaccine remains stable. We also aim to make sure that countries that have yet to introduce get the support they need to do so. Another important goal is that existing programmes are sustainable over the long term.
Advance Market Commitment
The implementation of this AMC is on track ... reducing morbidity and mortality from pneumococcal diseases in developing countries
Source: AMC process and design evaluation
The introduction of these vaccines is largely thanks to the generosity of Italy, the United Kingdom, Canada, the Russian Federation, Norway and the Bill & Melinda Gates Foundation. They have together contributed US$ 1.5 billion to the Advance Market Commitment (AMC) for pneumococcal vaccines.
The AMC aims to stimulate the development and manufacture of new vaccines for developing countries.
Two manufacturers have thus far committed to supply 600 million doses over the next 10 years. We expect that other manufacturers will have new vaccines ready to take part in the AMC in future years.
Map of countries approved for Gavi's pneumococcal vaccine support